Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004455264 | SCV004944634 | uncertain significance | Inborn genetic diseases | 2024-01-30 | criteria provided, single submitter | clinical testing | The c.64C>T (p.R22W) alteration is located in exon 1 (coding exon 1) of the SDCCAG8 gene. This alteration results from a C to T substitution at nucleotide position 64, causing the arginine (R) at amino acid position 22 to be replaced by a tryptophan (W). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005015142 | SCV005647356 | uncertain significance | Senior-Loken syndrome 7; Bardet-Biedl syndrome 16 | 2024-06-17 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004736437 | SCV005364599 | uncertain significance | SDCCAG8-related disorder | 2024-04-25 | no assertion criteria provided | clinical testing | The SDCCAG8 c.64C>T variant is predicted to result in the amino acid substitution p.Arg22Trp. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0039% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |